Principal & Head of Due Diligence
and access,
Devin Rosenthal, Principal & Head of Due Diligence at NovaQuest Capital Management, has broad operational and strategic experience across a range of therapeutic areas, stages of development, and company types within the biopharmaceutical industry. He is responsible for due diligence, sourcing, structuring of investment opportunities, and post-close investment management. Prior to joining NovaQuest, Dr. Rosenthal was a Senior Consultant at Triangle Insights Group, a boutique life sciences strategy consulting firm, where he focused on corporate strategy, due diligence, mergers and acquisitions, and commercial forecasting. His earlier experience includes work in product development and regulatory affairs at Rho, a mid-size contract research organization; companion diagnostics at Novartis Oncology; and clinical development at Boston Biomedical Inc, all following postdoctoral training at Tufts University’s Molecular Oncology Research Institute. Dr. Rosenthal earned a PhD in Cellular and Molecular Biology from the University of Michigan, an executive MBA from the Kenan-Flagler Business School at the University of North Carolina at Chapel Hill (Finance concentration), and a BS in Biology from the University of North Carolina at Wilmington.
